

# Administering Vaccines to Adults: Dose, Route, Site, and Needle Size

Vaccine	Dose	Route
<b>COVID-19</b> For product and dosage information for COVID-19 vaccine, see <a href="http://immunize.org's">immunize.org's</a> "Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Supply Tools" at <a href="http://www.immunize.org/catg.d/p3130.pdf">www.immunize.org/catg.d/p3130.pdf</a>		IM
<b>Hepatitis A (HepA)</b>	≤18 yrs: 0.5 mL; ≥19 yrs: 1.0 mL	IM
<b>Hepatitis B (HepB)</b>	<i>Engerix-B; Recombivax HB</i> ≤19 yrs: 0.5 mL, ≥20 yrs: 1.0 mL <i>Hepilisav-B: ≥18 yrs: 0.5 mL</i>	IM
<b>HepA-HepB (Twinrix)</b>	≥18 yrs: 1.0 mL	IM
<b>Human papillomavirus (HPV)</b>	0.5 mL	IM
<b>Influenza, live attenuated (LAIV)</b>	0.2 mL (0.1 mL in each nostril)	Intranasal spray
<b>Influenza, inactivated (IIV) and</b> • Cell-culture based (ccIIV, Flucelvax), 3+ yrs • Recombinant (RIV, Flublok) 18+ yrs • Adjuvanted (aIIV, Fluad) 65+ yrs <sup>1</sup> • High-dose (HD-IIV, Fluzone High Dose) 65+ yrs <sup>1</sup>	0.5 mL	IM
<b>Measles, Mumps, Rubella (MMR)</b>	0.5 mL	<i>MMR II (Merck)</i> IM or Subcut <i>Priorix (GSK)</i> Subcut
<b>Meningococcal serogroups A, C, W, Y (MenACWY)</b>	0.5 mL	IM
<b>Meningococcal serogroup B (MenB)</b>	0.5 mL	IM
<b>Meningococcal serogroups A, B, C, W, Y (MenABCWY)</b>	0.5 mL	IM
<b>Mpox (Jynneos)</b>	0.5 mL	Subcut <sup>2</sup>
<b>Pneumococcal conjugate (PCV)</b>	0.5 mL	IM
<b>Pneumococcal polysaccharide (PPSV23)</b>	0.5 mL	IM or Subcut
<b>Respiratory Syncytial Virus (RSV) vaccine</b>	0.5 mL	IM
<b>Tetanus, Diphtheria (Td) with Pertussis (Tdap)</b>	0.5 mL	IM
<b>Varicella (VAR)</b>	0.5 mL	IM or Subcut
<b>Zoster (RZV, Shingrix)</b>	0.5 <sup>3</sup> mL	IM

1 HD-IIV or aIIV are also options for solid organ transplant recipients 18–64 yrs on an immunosuppressive medication regimen.

2 Administration of Jynneos subcut (0.5 mL) is preferred. If an adult patient desires intradermal administration (0.1 mL) it is permitted under FDA emergency use authorization (see [www.fda.gov/media/160774/download](http://www.fda.gov/media/160774/download)).


3 The Shingrix (RZV) vial may contain more than 0.5 mL. Do not administer more than 0.5 mL.

## Injection Site and Needle Size


\* Alternate needle lengths may be used if the skin is stretched tightly and subcutaneous tissues are not bunched, as follows: a) a 5/8" needle for patients weighing less than 130 lbs (<60 kg) for IM injection in the deltoid muscle **only**, or b) a 1" needle for IM injection in the anterolateral thigh muscle for adults of any weight.

<b>Subcutaneous (Subcut) injection</b> – Use a 23–25 gauge, 5/8" needle. Inject in fatty tissue over triceps.		
<b>Intramuscular (IM) injection</b> – Use a 22–25 gauge needle. Choose the needle length and site as indicated below:		
BIOLOGICAL SEX AND WEIGHT OF PATIENT	NEEDLE LENGTH	INJECTION SITE
Female or male less than 130 lbs	5/8"* – 1"	Deltoid muscle of arm
Female or male 130–152 lbs	1"	
Female 153–200 lbs	1" – 1½"	
Male 153–260 lbs		
Female 200+ lbs	1½"	Anterolateral thigh
Male 260+ lbs		
Female or male, any weight	1"* – 1½"	

## Intramuscular (IM) injection



## Subcutaneous (Subcut) injection



## Intranasal (NAS) administration of Flumist (LAIV) vaccine



**NOTE:** Always refer to the package insert (found at [www.immunize.org/official-guidance/fda/pkg-inserts](http://www.immunize.org/official-guidance/fda/pkg-inserts)) included with each biologic for complete vaccine administration information. CDC's Advisory Committee on Immunization Practices (ACIP) recommendations for the particular vaccine should be reviewed as well. Access the ACIP recommendations at [www.immunize.org/official-guidance/cdc/acip-recs/vaccines](http://www.immunize.org/official-guidance/cdc/acip-recs/vaccines).

